Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Top Cited Papers
- 23 April 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (10), 3474-3477
- https://doi.org/10.1021/jm050069n
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and SensitizationScience, 2004
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Nicotinic Acetylcholine Receptors as Drug TargetsCurrent Drug Targets-CNS & Neurological Disorders, 2004
- Estimates of global mortality attributable to smoking in 2000The Lancet, 2003
- Cellular mechanisms of nicotine addictionPharmacology Biochemistry and Behavior, 2001
- Role of dopamine in the behavioural actions of nicotine related to addictionEuropean Journal of Pharmacology, 2000
- Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine.Psychopharmacology, 2000
- The Distribution of Neuronal Nicotinic Acetylcholine ReceptorsPublished by Springer Science and Business Media LLC ,2000
- Blockade of Nicotine Self-Administration with Nicotinic Antagonists in RatsPharmacology Biochemistry and Behavior, 1999
- Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotineNature, 1998